dariohealth.investorroom.com Open in urlscan Pro
2606:4700::6811:cb9f  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About us
   * Our Story
   * Clinical Research
   * Careers
   * Articles
   * Diversity & Inclusion
 * Our Solutions
   * Metabolic Solutions
   * Musculoskeletal Solutions
   * Behavioral Health Solutions
 * For Organizations
   * Health Plans
   * Employers
   * Providers
 * For Investors
   * Events & Presentations
   * Press Releases
   * Corporate Governance
   * Filings
   * Stock Info
   * Alerts
   * FAQs
 * Shop
   * Dario Store
   * Diabetes
   * Hypertension
   * Weight
   * Memberships

CONTACT US


PRESS RELEASES


DARIOHEALTH ENTERS INTO STRATEGIC AGREEMENT WITH SANOFI U.S.


NOVEL STRATEGIC AGREEMENT FOCUSES ON COMMERCIAL GROWTH FOR DARIO AND THE
DEVELOPMENT OF DIGITAL HEALTH SOLUTIONS ON DARIO'S PLATFORM

Mar 1, 2022

NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a
leader in the global digital therapeutics (DTx) market, announced it has entered
into a strategic agreement with Sanofi U.S., an innovative global healthcare
company. The multi-year, $30 million-dollar agreement, which is subject to
certain contingencies, will help accelerate commercial adoption of Dario's full
suite of digital therapeutics and drive the expansion of digital health
solutions on the Dario platform.  



Dario and Sanofi will collaborate on promoting the Dario multi-condition digital
therapeutics solution, significantly increasing Dario's sales reach in the
health plan market and selectively in the employer channel. In addition, the
agreement calls for Dario and Sanofi to develop new or enhanced solutions
leveraging the Dario platform, and for the parties to generate robust evidence
to support future commercialization in the health plan channel.   

Sanofi selected Dario to leverage its broad suite of digital therapeutics and
its ability to engage patients for favorable clinical and financial outcomes, as
the solution of choice for its U.S. commercial clients. Dario's single platform
helps patients manage diabetes, hypertension, weight management, musculoskeletal
and behavioral health, offering Sanofi managed care clients an attractive,
easily scalable digital health solution that creates immediate access across a
wide range of needs.

"We are thrilled to be chosen by Sanofi to expand into the digital health
market. We believe that this is the first time that a large biopharmaceutical
company and a digital health company are collaborating to commercialize digital
health solutions in the U.S. market. Dario's proven digital therapeutic
solutions and innovative technologies provide the perfect complement to Sanofi's
scientific expertise, market access and scale, creating a foundation for
long-term success in support of Sanofi's goal of expanding into digital health
therapies for chronic conditions," said Erez Raphael, CEO, DarioHealth.

"Our collaboration with Dario is another step towards accelerating Sanofi's
mission of reversing the course of chronic diseases through the integration of
healthcare and technology in a way that gives people the tools to improve their
health," said Gustavo Pesquin, Head, U.S. General Medicines, Sanofi. "We are
excited to help payers realize the potential digital health can bring to the
patient experience, and we look forward to continuing to innovate with Dario on
the next generation of chronic condition therapies."

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics
company revolutionizing how people with chronic conditions manage their health.
DarioHealth offers one of the most comprehensive digital therapeutics solutions
on the market - covering multiple chronic conditions including diabetes,
hypertension, weight management, musculoskeletal and behavioral health within
one integrated technology platform.

Dario's next-generation, AI-powered, digital therapeutic platform supports more
than just an individual's disease. Dario provides adaptive, personalized
experiences that drive behavior change through evidence-based interventions,
intuitive, clinically proven digital tools, high-quality software, and coaching
to help individuals improve health and sustain meaningful outcomes.

Dario's unique user-centric approach to product design and engagement creates an
unparalleled experience that is highly rated by users and delivers sustainable
results.

The company's cross-functional team operates at the intersection of life
sciences, behavioral science, and software technology and utilizes a
performance-based approach to improve its users' health.

On the path to better health, Dario makes the right thing to do the easy thing
to do. To learn more about DarioHealth and its digital health solutions or for
more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of
DarioHealth Corp. related thereto contain or may contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Statements that are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using forward-looking
statements in this press release when it discusses the potential value of the
agreement and that the agreement will help accelerate commercial adoption of
Dario's full suite of digital therapeutics and drive the expansion of digital
health solutions on the Dario platform, the benefits that may be realized by the
Dario solution and that the collaboration creates the foundation for long-term
success in support of Sanofi's goal of expanding into digital health therapies
for chronic conditions. Without limiting the generality of the foregoing, words
such as "plan," "project," "potential," "seek," "may," "will," "expect,"
"believe," "anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are cautioned that
certain important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking statements that
may be made in this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product development,
commercialization or technological difficulties, the success or failure of
negotiations and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional factors that
could cause or contribute to differences between the Company's actual results
and forward-looking statements include, but are not limited to, those risks
discussed in the Company's filings with the U.S. Securities and Exchange
Commission. Readers are cautioned that actual results (including, without
limitation, the timing for and results of the Company's commercial and
regulatory plans for Dario™ as described herein) may differ significantly from
those set forth in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by
applicable law.

DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220

Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262

 



SOURCE DarioHealth Corp.



LET'S GET STARTED

To arrange a demo and learn more about the many benefits of offering Dario to
your employees, members, or patients, contact us today.

Get started
Contact Us

FOLLOW US


Supported Devices

DARIO SUPPORT TOLL-FREE: 833-914-3796

© 2022 DarioHealth Corp. View our Privacy Policy or Terms and Conditions

DarioHealth is a publicly traded company (Nasdaq: DRIO).

Supported Devices

iOS Application version – 4.3.1
Supported iOS phones (Audio Jack): iPhone 5, 5s, SE, 6, 6 Plus, 6s, 6s Plus

Supported iOS phones (LC): 7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, XR, 11, 11 Pro,
11 Pro Max, SE 2020
iOS Operating System: 10, 11, 12, 13

(*) Note: iPhone7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, Xr are supported with the
product Dario LC Blood Glucose Monitoring System.

Android Application version – 4.5.0

Supported Android phones (Audio Jack):
LG G6, G7, G8.
Samsung Galaxy S6, S6 Edge, S7, S7 Edge, S8, S8+, S9, S9+, S10, S10+, S10e, S10
5G.
Galaxy Note 4, 5, 8, 9

Supported Android phones (USB-C):
LG G6, G7, G8.
Samsung Galaxy S8, S8+, S9, S9+, S10, S10+, S10e, S10 5G, S20, S20+, S20 Ultra.
Galaxy Note 8, 9, 10, 10+
Google Pixel 3, 3 XL, 4, 4 XL

Android Operating System: 6, 7, 8, 9

×